The study, published in CVIR Oncology, draws on the CIRT registry spanning 27 sites across eight European countries and its French counterpart, CIRT-FR, which was conducted to help the French Health Authority evaluate reimbursement of yttrium-90 resin microspheres. Both registries were designed to capture real-world clinical practice rather than the tightly scripted conditions of a randomized trial, and that realism is precisely what makes the findings interesting. Physicians recorded their planned treatment intent at the start of therapy, but the researchers later reclassified each patient’s actual trajectory using predefined criteria covering transplantation, ablation, resection, or a sustained complete response lasting at least one year as measured by modified RECIST criteria.

The headline numbers tell a story about the gap between intention and outcome. Although 229 of the 615 patients, roughly 37 percent, were initially slated for curative-intent treatment pathways, only 40 patients, or 6.5 percent, ultimately met the retrospective curative-intent definition, while 93 percent were classified as palliative. Of those 40, half went on to liver transplantation after TARE, seven received ablation and two underwent resection. Most remarkably, 11 patients, 27.5 percent of the curative group, required no further treatment at all because TARE alone had produced a complete tumor response documented for at least a year.

That last figure carries particular weight given how the authors framed their expectations. Among 32 patients whose a priori plan was radiation segmentectomy, meaning planned curative yttrium-90 monotherapy, only one ultimately achieved a curative classification through subsequent transplantation. In other words, the patients who ended up cured by radiation alone were rarely the ones selected for that purpose in advance. Their complete responses were, in a sense, discovered rather than engineered, which the authors say underscores how little consensus currently exists on who will convert to a curative pathway after radioembolization and how urgently refined conversion criteria are needed.

The statistical analysis offers some clues. In multivariable logistic regression, three factors independently predicted placement in the curative-intent group: an ECOG performance status of zero, corresponding to fully active patients, carried an odds ratio of 0.44; having one to three tumors yielded an odds ratio of 0.39; and a total tumor volume below 150 cubic centimeters produced an odds ratio of 0.40. That 150 cubic centimeter threshold emerged from receiver operating characteristic analysis as one of two optimal cut points for separating curative from palliative patients, and it was selected for its higher specificity of 0.725. Notably, 72.5 percent of curatively treated patients fell below this volume, which is substantially larger than the roughly 65 cubic centimeter ceiling imposed by the classic Milan criteria for transplantation eligibility.

This discrepancy is central to the paper’s argument. The Milan criteria, which have governed transplant selection for hepatocellular carcinoma for nearly three decades, rest almost entirely on morphometric measurements, and the authors found no significant differences between their curative and palliative groups on Milan-based eligibility before treatment. Around 80 percent of the curatively managed patients were outside Milan criteria before TARE. The implication is that radioembolization can shrink tumors enough to pull patients back within transplant boundaries, and that tumor volume thresholds well beyond Milan’s limits, combined with biological markers such as alpha-fetoprotein and the ALBI grade of liver function, may better identify who stands to benefit. The authors point to emerging tools like the Metroticket 2.0 model as the kind of finer-grained metrics the field needs.

Dosimetry adds another technical layer to the story. Because absorbed radiation doses were not prospectively collected in the original registries, the team recalculated them retrospectively using the simplified Medical Internal Radiation Dose formula, dividing administered activity by tumor mass. Their surrogate analysis found that absorbed doses above 400 grays correlated with longer survival, a threshold repeatedly associated with complete response in prior literature. Crucially, 92.3 percent of patients who received doses above that level had tumors under 150 cubic centimeters, suggesting that the concentration of radiation achievable in smaller, more selectively targeted volumes is what drives these dramatic responses. Yet the data also showed that doses exceeding 400 grays remained effective in tumors up to about 150 cubic centimeters, roughly 6.6 centimeters in diameter, larger than many earlier studies had considered treatable at such intensities.

Survival outcomes reinforce the signal. Median overall survival was not reached in the complete response, resection, and ablation subgroups by the end of follow-up, and in the transplantation subgroup, 75 percent and 85 percent survival percentiles were reached at 37.1 and 11.4 months respectively, with only one death recorded in the resection and ablation group and none in the complete response group. By contrast, the palliative group’s median survival of 16.1 months compares favorably with the 8.0 and 8.8 months reported in the landmark SARAH and SIRveNIB randomized trials of radioembolization versus sorafenib in advanced disease, and aligns with more recent prospective figures of 13.9 months. The real-world palliative performance alone is notable, but the theoretical cure fractions achieved in a minority of patients are what will spark debate.

The authors are careful about the limits of their evidence. This was an exploratory, retrospective classification layered onto prospective observational data, with no harmonized definition of curative intent when the studies began. Baseline characteristics were collected only before TARE, alpha-fetoprotein levels were missing in more than a fifth of curative patients and more than 40 percent of palliative patients, and dosimetry relied on a surrogate calculation. The heterogeneity of post-TARE curative procedures across different national practices further complicates generalization. Still, the conclusion is clear and consequential: yttrium-90 radioembolization belongs not just in the palliative toolbox but across the full spectrum of curative-intent strategies for hepatocellular carcinoma, whether as a bridge to transplantation, a downstaging tool before resection or ablation, or, in carefully selected patients with small tumor burdens and good performance status, as a standalone therapy capable of eradicating the disease outright. The task now facing the field, the authors argue, is to marry morphometry, tumor biology, and personalized dosimetry into reliable criteria that can identify, before the first microsphere is injected, which patients will be among the lucky few whose cancer never returns.

Subject of Research: Curative-intent transarterial radioembolization with yttrium-90 in hepatocellular carcinoma

Article Title: Hepatocellular carcinoma patients treated with TARE monotherapy or combination therapy with curative intent: a retrospective, exploratory analysis of two European prospective studies

Article References: Helmberger, T., Arnold, D., Loffroy, R., Ronot, M., Sangro, B., Kolligs, F., Pellerin, O., Maleux, G., Peynircioglu, B., Schaefer, N., Bilbao, J. I., de Jong, N., Geyer, M., Zeka, B., Urdaniz, M., & Vilgrain, V. (2026). Hepatocellular carcinoma patients treated with TARE monotherapy or combination therapy with curative intent: a retrospective, exploratory analysis of two European prospective studies. CVIR Oncology, 2(1), Article 5. https://doi.org/10.1007/s44343-026-00035-5

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00035-5

Keywords: hepatocellular carcinoma, TARE, yttrium-90, radioembolization, liver transplantation, radiation segmentectomy, Milan criteria, dosimetry, tumor downstaging, locoregional therapy, complete response, CIRT registry

The study, published in CVIR Oncology, analyzed data from the CIRSE Registry for SIR-Spheres Therapy, known as CIRT, a Europe-wide observational study conducted in eight countries across 27 centers. Of the 1,036 patients enrolled with primary or secondary liver malignancies, the researchers focused on 169 adults whose liver metastases originated from neuroendocrine tumors, breast cancer, pancreatic cancer, or melanoma. All were treated with yttrium-90 resin microspheres, tiny radioactive spheres delivered through the hepatic artery that lodge in the small vessels feeding tumors and deliver high-dose internal radiation while sparing most healthy tissue.

The technical logic behind TARE is elegant. Unlike conventional external beam radiotherapy, which must pass through healthy tissue to reach its target, radioembolization exploits the fact that liver tumors draw their blood supply predominantly from the hepatic artery, while healthy liver tissue depends on the portal vein. Catheters threaded from a puncture in the groin or wrist guide the microspheres into the arteries supplying the tumors, where the beta radiation from yttrium-90, which travels only a few millimeters in tissue, kills cancer cells from within. Before treatment, teams perform careful mapping angiography and dosimetry, often using the body surface area method or a partition model, to calculate the activity to be injected and to avoid reflux of spheres into the stomach or bowel.

The survival results varied dramatically by tumor type, underscoring how different these diseases are. Patients with neuroendocrine tumors fared best, with a median overall survival of 33.3 months after treatment. Those with breast cancer liver metastases had a median survival of 10.7 months, while patients with melanoma reached 14.7 months. Pancreatic cancer, notoriously aggressive even when it has spread only to the liver, showed the poorest outcome at 5.6 months. Median follow-up ranged from 5.6 months in the pancreatic cohort to 19.3 months in the neuroendocrine group, and patients were enrolled between January 2015 and December 2017 with follow-up through the end of 2019.

Safety was the study’s most consistent message. Severe adverse events of grade three or higher, defined according to the standard CTCAE criteria, occurred in just 10 percent of all 169 patients. Procedure-related adverse events were predominantly mild to moderate, affecting roughly one in five neuroendocrine and breast cancer patients and only about six percent of those with pancreatic cancer or melanoma. Predefined serious events tracked in the registry included abdominal pain, fatigue, fever, nausea, vomiting, gastrointestinal ulceration, gastritis, and radiation cholecystitis, but these remained uncommon. For a therapy that delivers ionizing radiation directly into a vital organ, this safety profile across four very different tumor types is a notable result.

Perhaps the most scientifically intriguing findings came from the multivariable analysis, in which the researchers used Cox proportional hazards models to identify independent predictors of survival. Two laboratory-based markers emerged repeatedly. The Albumin-Bilirubin grade, or ALBI, which combines liver synthetic function with bile clearance, predicted worse overall survival in both the neuroendocrine and breast cancer cohorts, with hazard ratios above four. The Aspartate transaminase to Platelet Ratio Index, or APRI, a marker usually associated with liver fibrosis, predicted poorer survival in the neuroendocrine and melanoma cohorts. In melanoma patients the effect was striking: an APRI value above 0.40 carried a hazard ratio of 37.63 for death, an extraordinarily strong association. In breast cancer patients, an international normalized ratio above one and an elevated neutrophil-to-leukocyte ratio also predicted worse progression-free survival.

These biomarker findings carry practical weight. They suggest that the health of the underlying liver, and possibly the systemic inflammatory state reflected in blood counts, shapes how much patients benefit from internal radiation, and that the relevant markers differ by tumor type. The authors argue this supports individualized patient assessment that incorporates both the histology of the metastases and routine laboratory evaluation. It also hints that simple blood tests available before treatment could help clinicians select which patients are most likely to benefit, an increasingly important question as liver-directed therapies proliferate.

Context matters for interpreting the survival numbers. For neuroendocrine liver metastases, which develop in up to 80 percent of patients with these tumors, the 33.3 month median survival aligns closely with a systematic review of 809 patients that reported a pooled overall survival of 33 months, and with the American RESiN registry, which reported a median of 33 months. For breast cancer, the 10.7 month result is comparable to a meta-analysis of 452 patients that found a median of 11.3 months. In melanoma, where nearly 60 percent of the study’s patients received TARE as first-line liver-directed therapy, the 14.7 month median sits comfortably within the 9 to 24 month range reported across systematic reviews of radioembolization for uveal melanoma. The pancreatic cancer result, while bleak, reflects a disease in which even surgery and modern chemotherapy yield median survivals under a year in the metastatic liver setting.

The study’s authors are careful about its limits. As an observational registry without a control group, it cannot prove that TARE is superior to other options, and selection bias and residual confounding cannot be excluded. The lack of a standardized treatment protocol across 27 centers introduced heterogeneity in baseline characteristics, treatment timing, and surrounding systemic therapies. Missing data may have affected some analyses, and no multivariable model was possible for the pancreatic cohort because too few variables reached the significance threshold. What the study does provide is something rarer: prospectively collected, multicenter, real-world evidence about how TARE is actually used and how patients actually fare when multidisciplinary teams choose it for tumors that fall outside existing guidelines.

That guideline gap is precisely why the results matter. TARE is a standard of care for intermediate to advanced hepatocellular carcinoma and for metastatic colorectal cancer, but for non-colorectal liver metastases, formal recommendations have been largely absent; the European Neuroendocrine Tumour Society recently noted that no data existed on liver embolization for neuroendocrine carcinoma. By documenting safety and encouraging effectiveness in 169 patients across four tumor types, the CIRT analysis gives clinicians a firmer evidence footing for a treatment many were already offering, and it sets a clear agenda: prospective comparative studies are now needed to identify which patient groups benefit most, and simple markers like ALBI and APRI may help decide who should be offered the radioactive beads and who should be spared the procedure.

Subject of Research: Yttrium-90 transarterial radioembolization for non-colorectal liver metastases

Article Title: Transarterial radioembolization for liver metastases of non-colorectal origin: safety and effectiveness results from the prospective multicenter CIRSE registry for SIR-spheres therapy (CIRT)

Article References: Arnold, D., Chlorogiannis, D. D., Sangro, B., Kolligs, F., Maleux, G., Bilbao, J. I., Pech, M., Pfammatter, T., de Jong, N., Geyer, M., Urdániz, M., & Helmberger, T. (2026). Transarterial radioembolization for liver metastases of non-colorectal origin: safety and effectiveness results from the prospective multicenter CIRSE registry for SIR-spheres therapy (CIRT). CVIR Oncology, 2(1), Article 6. https://doi.org/10.1007/s44343-026-00039-1

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00039-1

Keywords: transarterial radioembolization, yttrium-90, liver metastases, neuroendocrine tumors, breast cancer, pancreatic cancer, melanoma, SIR-Spheres, CIRT registry, ALBI grade, APRI, interventional radiology